| Antibiotic . | Susceptibility . | CP-CRE (n = 14) . | Non-CP CRE (n = 9) . | Unconfirmed CRE (n = 18) . |
|---|---|---|---|---|
| Amikacin | Resistant | 4 (20%) | 0 (0%) | 1 (9%) |
| Intermediate | 3 (30%) | 0 (0%) | 2 (18%) | |
| Susceptible | 5 (50%) | 4 (100%) | 8 (73%) | |
| Not tested | 2 | 5 | 7 | |
| Aztreonam | Resistant | 8 (100%) | 6 (100%) | 6 (67%) |
| Susceptible | 0 | 0 | 3 (33%) | |
| Not tested | 6 | 3 | 9 | |
| Cefepime | Resistant | 11 (92%) | 2 (25%) | 4 (24%) |
| Intermediate | 1 (8%) | 2 (25%) | 3 (19%) | |
| Susceptible | 0 (0%) | 4 (50%) | 9 (56%) | |
| Not tested | 2 | 1 | 2 | |
| Ceftazidime-avibactam | Resistant | 3 (100%) | 0 | 0 |
| Susceptible | 0 | 1 (100%) | 0 | |
| Not tested | 11 | 17 | 18 | |
| Ceftriaxone | Resistant | 13 (93%) | 5 (100%) | 14 (93%) |
| Susceptible | 1 (7%) | 0 | 1 (7%) | |
| Not tested | 0 | 4 | 3 | |
| Ciprofloxacin | Resistant | 7 (64%) | 1 (14%) | 4 (31%) |
| Susceptible | 4 (36%) | 6 (86%) | 9 (69%) | |
| Not tested | 3 | 2 | 5 | |
| Colistin | Resistant | 0 | 0 | 1(50%) |
| Intermediate | 1 (33%) | 0 | 0 | |
| Susceptible | 2 (67%) | 1(100%) | 1 (50%) | |
| Not tested | 11 | 8 | 16 | |
| Ertapenem | Resistant | 12 (100%) | 8 (100%) | 17 (100%) |
| Not tested | 2 | 1 | 1 | |
| Gentamicin | Resistant | 11 (46%) | 0 | 13 (26%) |
| Intermediate | 0 | 0 | 4 (8%) | |
| Susceptible | 3 (54%) | 8 (100%) | 33 (66%) | |
| Not tested | 0 | 1 | 1 | |
| Imipenem | Resistant | 7 (78%) | 0 | 3 (30%) |
| Intermediate | 2 (22%) | 1 (25%) | 0 | |
| Susceptible | 0 (0%) | 3 (75%) | 7 (70%) | |
| Not tested | 5 | 5 | 8 | |
| Meropenem | Resistant | 12 (92%) | 2 (25%) | 9 (53%) |
| Intermediate | 1 (8%) | 2(25%) | 0 | |
| Susceptible | 0 | 4 (50%) | 8 (47%) | |
| Not tested | 1 | 1 | 1 | |
| Polymyxin/b | Resistant | 1 (25%) | 0 | 0 |
| Susceptible | 3 (75%) | 0 | 0 | |
| Not tested | 10 | 9 | 18 | |
| Piperacillin-tazobactam | Resistant | 12 (100%) | 5 (62%) | 6 (33%) |
| Intermediate | 0 (0%) | 3 (38%) | 3 (17%) | |
| Susceptible | 0 (0%) | 0 | 9 (50%) | |
| Not tested | 2 | 1 | 0 | |
| Tobramycin | Resistant | 8 (67%) | 1 (20%) | 2 (14%) |
| Intermediate | 0 (0%) | 0 | 3 (21%) | |
| Susceptible | 4 (33%) | 4 (80%) | 9 (64%) | |
| Not tested | 2 | 4 | 10 | |
| Trimethoprim-sulfamethoxazole | Resistant | 8 (62%) | 4 (50%) | 4 (24%) |
| Susceptible | 5 (38%) | 4 (50%) | 13 (76%) | |
| Not tested | 1 | 1 | 1 |
| Antibiotic . | Susceptibility . | CP-CRE (n = 14) . | Non-CP CRE (n = 9) . | Unconfirmed CRE (n = 18) . |
|---|---|---|---|---|
| Amikacin | Resistant | 4 (20%) | 0 (0%) | 1 (9%) |
| Intermediate | 3 (30%) | 0 (0%) | 2 (18%) | |
| Susceptible | 5 (50%) | 4 (100%) | 8 (73%) | |
| Not tested | 2 | 5 | 7 | |
| Aztreonam | Resistant | 8 (100%) | 6 (100%) | 6 (67%) |
| Susceptible | 0 | 0 | 3 (33%) | |
| Not tested | 6 | 3 | 9 | |
| Cefepime | Resistant | 11 (92%) | 2 (25%) | 4 (24%) |
| Intermediate | 1 (8%) | 2 (25%) | 3 (19%) | |
| Susceptible | 0 (0%) | 4 (50%) | 9 (56%) | |
| Not tested | 2 | 1 | 2 | |
| Ceftazidime-avibactam | Resistant | 3 (100%) | 0 | 0 |
| Susceptible | 0 | 1 (100%) | 0 | |
| Not tested | 11 | 17 | 18 | |
| Ceftriaxone | Resistant | 13 (93%) | 5 (100%) | 14 (93%) |
| Susceptible | 1 (7%) | 0 | 1 (7%) | |
| Not tested | 0 | 4 | 3 | |
| Ciprofloxacin | Resistant | 7 (64%) | 1 (14%) | 4 (31%) |
| Susceptible | 4 (36%) | 6 (86%) | 9 (69%) | |
| Not tested | 3 | 2 | 5 | |
| Colistin | Resistant | 0 | 0 | 1(50%) |
| Intermediate | 1 (33%) | 0 | 0 | |
| Susceptible | 2 (67%) | 1(100%) | 1 (50%) | |
| Not tested | 11 | 8 | 16 | |
| Ertapenem | Resistant | 12 (100%) | 8 (100%) | 17 (100%) |
| Not tested | 2 | 1 | 1 | |
| Gentamicin | Resistant | 11 (46%) | 0 | 13 (26%) |
| Intermediate | 0 | 0 | 4 (8%) | |
| Susceptible | 3 (54%) | 8 (100%) | 33 (66%) | |
| Not tested | 0 | 1 | 1 | |
| Imipenem | Resistant | 7 (78%) | 0 | 3 (30%) |
| Intermediate | 2 (22%) | 1 (25%) | 0 | |
| Susceptible | 0 (0%) | 3 (75%) | 7 (70%) | |
| Not tested | 5 | 5 | 8 | |
| Meropenem | Resistant | 12 (92%) | 2 (25%) | 9 (53%) |
| Intermediate | 1 (8%) | 2(25%) | 0 | |
| Susceptible | 0 | 4 (50%) | 8 (47%) | |
| Not tested | 1 | 1 | 1 | |
| Polymyxin/b | Resistant | 1 (25%) | 0 | 0 |
| Susceptible | 3 (75%) | 0 | 0 | |
| Not tested | 10 | 9 | 18 | |
| Piperacillin-tazobactam | Resistant | 12 (100%) | 5 (62%) | 6 (33%) |
| Intermediate | 0 (0%) | 3 (38%) | 3 (17%) | |
| Susceptible | 0 (0%) | 0 | 9 (50%) | |
| Not tested | 2 | 1 | 0 | |
| Tobramycin | Resistant | 8 (67%) | 1 (20%) | 2 (14%) |
| Intermediate | 0 (0%) | 0 | 3 (21%) | |
| Susceptible | 4 (33%) | 4 (80%) | 9 (64%) | |
| Not tested | 2 | 4 | 10 | |
| Trimethoprim-sulfamethoxazole | Resistant | 8 (62%) | 4 (50%) | 4 (24%) |
| Susceptible | 5 (38%) | 4 (50%) | 13 (76%) | |
| Not tested | 1 | 1 | 1 |
Abbreviation: CP-CRE, carbapenem-resistant Enterobacterales isolates with a carbapenemase gene.
| Antibiotic . | Susceptibility . | CP-CRE (n = 14) . | Non-CP CRE (n = 9) . | Unconfirmed CRE (n = 18) . |
|---|---|---|---|---|
| Amikacin | Resistant | 4 (20%) | 0 (0%) | 1 (9%) |
| Intermediate | 3 (30%) | 0 (0%) | 2 (18%) | |
| Susceptible | 5 (50%) | 4 (100%) | 8 (73%) | |
| Not tested | 2 | 5 | 7 | |
| Aztreonam | Resistant | 8 (100%) | 6 (100%) | 6 (67%) |
| Susceptible | 0 | 0 | 3 (33%) | |
| Not tested | 6 | 3 | 9 | |
| Cefepime | Resistant | 11 (92%) | 2 (25%) | 4 (24%) |
| Intermediate | 1 (8%) | 2 (25%) | 3 (19%) | |
| Susceptible | 0 (0%) | 4 (50%) | 9 (56%) | |
| Not tested | 2 | 1 | 2 | |
| Ceftazidime-avibactam | Resistant | 3 (100%) | 0 | 0 |
| Susceptible | 0 | 1 (100%) | 0 | |
| Not tested | 11 | 17 | 18 | |
| Ceftriaxone | Resistant | 13 (93%) | 5 (100%) | 14 (93%) |
| Susceptible | 1 (7%) | 0 | 1 (7%) | |
| Not tested | 0 | 4 | 3 | |
| Ciprofloxacin | Resistant | 7 (64%) | 1 (14%) | 4 (31%) |
| Susceptible | 4 (36%) | 6 (86%) | 9 (69%) | |
| Not tested | 3 | 2 | 5 | |
| Colistin | Resistant | 0 | 0 | 1(50%) |
| Intermediate | 1 (33%) | 0 | 0 | |
| Susceptible | 2 (67%) | 1(100%) | 1 (50%) | |
| Not tested | 11 | 8 | 16 | |
| Ertapenem | Resistant | 12 (100%) | 8 (100%) | 17 (100%) |
| Not tested | 2 | 1 | 1 | |
| Gentamicin | Resistant | 11 (46%) | 0 | 13 (26%) |
| Intermediate | 0 | 0 | 4 (8%) | |
| Susceptible | 3 (54%) | 8 (100%) | 33 (66%) | |
| Not tested | 0 | 1 | 1 | |
| Imipenem | Resistant | 7 (78%) | 0 | 3 (30%) |
| Intermediate | 2 (22%) | 1 (25%) | 0 | |
| Susceptible | 0 (0%) | 3 (75%) | 7 (70%) | |
| Not tested | 5 | 5 | 8 | |
| Meropenem | Resistant | 12 (92%) | 2 (25%) | 9 (53%) |
| Intermediate | 1 (8%) | 2(25%) | 0 | |
| Susceptible | 0 | 4 (50%) | 8 (47%) | |
| Not tested | 1 | 1 | 1 | |
| Polymyxin/b | Resistant | 1 (25%) | 0 | 0 |
| Susceptible | 3 (75%) | 0 | 0 | |
| Not tested | 10 | 9 | 18 | |
| Piperacillin-tazobactam | Resistant | 12 (100%) | 5 (62%) | 6 (33%) |
| Intermediate | 0 (0%) | 3 (38%) | 3 (17%) | |
| Susceptible | 0 (0%) | 0 | 9 (50%) | |
| Not tested | 2 | 1 | 0 | |
| Tobramycin | Resistant | 8 (67%) | 1 (20%) | 2 (14%) |
| Intermediate | 0 (0%) | 0 | 3 (21%) | |
| Susceptible | 4 (33%) | 4 (80%) | 9 (64%) | |
| Not tested | 2 | 4 | 10 | |
| Trimethoprim-sulfamethoxazole | Resistant | 8 (62%) | 4 (50%) | 4 (24%) |
| Susceptible | 5 (38%) | 4 (50%) | 13 (76%) | |
| Not tested | 1 | 1 | 1 |
| Antibiotic . | Susceptibility . | CP-CRE (n = 14) . | Non-CP CRE (n = 9) . | Unconfirmed CRE (n = 18) . |
|---|---|---|---|---|
| Amikacin | Resistant | 4 (20%) | 0 (0%) | 1 (9%) |
| Intermediate | 3 (30%) | 0 (0%) | 2 (18%) | |
| Susceptible | 5 (50%) | 4 (100%) | 8 (73%) | |
| Not tested | 2 | 5 | 7 | |
| Aztreonam | Resistant | 8 (100%) | 6 (100%) | 6 (67%) |
| Susceptible | 0 | 0 | 3 (33%) | |
| Not tested | 6 | 3 | 9 | |
| Cefepime | Resistant | 11 (92%) | 2 (25%) | 4 (24%) |
| Intermediate | 1 (8%) | 2 (25%) | 3 (19%) | |
| Susceptible | 0 (0%) | 4 (50%) | 9 (56%) | |
| Not tested | 2 | 1 | 2 | |
| Ceftazidime-avibactam | Resistant | 3 (100%) | 0 | 0 |
| Susceptible | 0 | 1 (100%) | 0 | |
| Not tested | 11 | 17 | 18 | |
| Ceftriaxone | Resistant | 13 (93%) | 5 (100%) | 14 (93%) |
| Susceptible | 1 (7%) | 0 | 1 (7%) | |
| Not tested | 0 | 4 | 3 | |
| Ciprofloxacin | Resistant | 7 (64%) | 1 (14%) | 4 (31%) |
| Susceptible | 4 (36%) | 6 (86%) | 9 (69%) | |
| Not tested | 3 | 2 | 5 | |
| Colistin | Resistant | 0 | 0 | 1(50%) |
| Intermediate | 1 (33%) | 0 | 0 | |
| Susceptible | 2 (67%) | 1(100%) | 1 (50%) | |
| Not tested | 11 | 8 | 16 | |
| Ertapenem | Resistant | 12 (100%) | 8 (100%) | 17 (100%) |
| Not tested | 2 | 1 | 1 | |
| Gentamicin | Resistant | 11 (46%) | 0 | 13 (26%) |
| Intermediate | 0 | 0 | 4 (8%) | |
| Susceptible | 3 (54%) | 8 (100%) | 33 (66%) | |
| Not tested | 0 | 1 | 1 | |
| Imipenem | Resistant | 7 (78%) | 0 | 3 (30%) |
| Intermediate | 2 (22%) | 1 (25%) | 0 | |
| Susceptible | 0 (0%) | 3 (75%) | 7 (70%) | |
| Not tested | 5 | 5 | 8 | |
| Meropenem | Resistant | 12 (92%) | 2 (25%) | 9 (53%) |
| Intermediate | 1 (8%) | 2(25%) | 0 | |
| Susceptible | 0 | 4 (50%) | 8 (47%) | |
| Not tested | 1 | 1 | 1 | |
| Polymyxin/b | Resistant | 1 (25%) | 0 | 0 |
| Susceptible | 3 (75%) | 0 | 0 | |
| Not tested | 10 | 9 | 18 | |
| Piperacillin-tazobactam | Resistant | 12 (100%) | 5 (62%) | 6 (33%) |
| Intermediate | 0 (0%) | 3 (38%) | 3 (17%) | |
| Susceptible | 0 (0%) | 0 | 9 (50%) | |
| Not tested | 2 | 1 | 0 | |
| Tobramycin | Resistant | 8 (67%) | 1 (20%) | 2 (14%) |
| Intermediate | 0 (0%) | 0 | 3 (21%) | |
| Susceptible | 4 (33%) | 4 (80%) | 9 (64%) | |
| Not tested | 2 | 4 | 10 | |
| Trimethoprim-sulfamethoxazole | Resistant | 8 (62%) | 4 (50%) | 4 (24%) |
| Susceptible | 5 (38%) | 4 (50%) | 13 (76%) | |
| Not tested | 1 | 1 | 1 |
Abbreviation: CP-CRE, carbapenem-resistant Enterobacterales isolates with a carbapenemase gene.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
